Daxor (DXR) 5-Year Share Buyback Ratio : -5.80% (As of Dec. 2024)

View and export this data going back to 1983. Start your Free Trial

What is Daxor 5-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Daxor's current 5-Year Share Buyback Ratio was -5.80%.

DXR's 5-Year Share Buyback Ratio is ranked worse than
57.93% of 656 companies
in the Medical Devices & Instruments industry
Industry Median: -3.8 vs DXR: -5.80

Competitive Comparison of Daxor's 5-Year Share Buyback Ratio

For the Medical Instruments & Supplies subindustry, Daxor's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daxor's 5-Year Share Buyback Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Daxor's 5-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Daxor's 5-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Daxor 5-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Daxor (NAS:DXR) 5-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Daxor 5-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Daxor's 5-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Daxor Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » 5-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

DX5:Germany

Address

109 Meco Lane, Oak Ridge, TN, USA, 37830

Website

https://www.daxor.com

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Executives

Michael Richard Feldschuh	director	71 GRAND STREET #2, NEW YORK NY 10013
Robert J Michel	officer: CHIEF FINANCIAL OFFICER	C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Edward Feuer	director	2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Joy S. Goudie	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers	director	DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Soren Thompson	officer: V.P./BUSINESS DEVELOPMENT	180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh	director, officer: CHIEF SCIENTIFIC OFFICER	DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh	officer: President	615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh	other: FOUNDER	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan	officer: Corporate Secretary	259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe	director	6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens	director	200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson	director	P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom	officer: Vice President	3244 BLACK FOX ROAD, WASHBURN TN 37888